18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy

Eric C. Ford, Joseph Herman, Ellen Yorke, Richard L. Wahl

Research output: Contribution to journalReview article

Abstract

Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. 18F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of 18F-FDG PET/CT in a variety of disease sites, including non-small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of 18F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.

Original languageEnglish (US)
Pages (from-to)1655-1665
Number of pages11
JournalJournal of Nuclear Medicine
Volume50
Issue number10
DOIs
StatePublished - Oct 1 2009

Keywords

  • FDG (fluorodeoxyglucose)
  • FDG PET/CT
  • IGRT
  • IMRT
  • Radiation therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '<sup>18</sup>F-FDG PET/CT for image-guided and intensity-modulated radiotherapy'. Together they form a unique fingerprint.

  • Cite this